ea0063gp57 | Acromegaly and GH | ECE2019
Gadelha Monica
, Colao Annamaria
, Bex Marie
, Mukherjee Rishav
, Bourad Catherine
, Maamari Ricardo
, Raverot Gerald
Background: In a phase 3b, open-label study (NCT02354508) assessing efficacy and safety of long-acting pasireotide in patients with uncontrolled acromegaly after ≥3 months of treatment with first-generation SSAs, 18/123 (15%) patients achieved the primary endpoint of mean growth hormone (mGH) <1.0 μg/l and insulin-like growth factor-1 (IGF-1) <ULN (upper limit of normal) at week 36. Here, we present the results from the extension phase of this study.<p c...